Breaking News Instant updates and real-time market news.

NYCB

New York Community Bancorp

$9.65

(0.00%)

, GBT

Global Blood Therapeutics

$57.45

(0.00%)

09:40
06/14/19
06/14
09:40
06/14/19
09:40

Unusually active option classes on open June 14th

Unusual total active option classes on open include: New York Community Bancorp (NYCB), Global Blood Therapeutics (GBT), Broadcom (AVGO), Disney (DIS), Facebook (FB), Direxion Junior Gold (JNUG), Starbucks (SBUX), Barrick Gold (GOLD), Lululemon (LULU), and iShares Silver Trust (SLV).

NYCB

New York Community Bancorp

$9.65

(0.00%)

GBT

Global Blood Therapeutics

$57.45

(0.00%)

AVGO

Broadcom

$281.95

(0.00%)

DIS

Disney

$141.73

(0.00%)

FB

Facebook

$177.47

(0.00%)

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$8.96

(0.00%)

SBUX

Starbucks

$83.36

(0.00%)

GOLD

Barrick Gold

$13.86

(0.00%)

LULU

Lululemon

$174.51

(0.00%)

SLV

iShares Silver Trust

$13.95

(0.00%)

  • 14

    Jun

  • 18

    Jun

  • 25

    Jun

  • 25

    Jun

  • 09

    Jul

  • 09

    Jul

  • 10

    Jul

NYCB New York Community Bancorp
$9.65

(0.00%)

06/12/19
KBWI
06/12/19
NO CHANGE
KBWI
New York rent reforms avoid 'worst case scenario,' says Keefe Bruyette
New York Assembly Speaker Carl Heastie and State Senate Majority Leader Andrea Stewart Cousins announced last Tuesday an agreement on New York rent reforms, Keefe Bruyette analyst Collyn Gilbert wrote earlier in a research note to investors. The reforms agreed upon have no expiration date unlike prior rent laws and did not end up in the "worst case scenario" for New York multifamily lenders, says the analyst. She believes the new laws resulted in more of a compromise between tenant and building owners' rights. While the new rent rules bring a "very sharp and disappointing difference" to the operating environment from the past 15 years, the overhaul avoided the "worst case scenario" of abolishing major capital improvement rent increases, contends Gilbert. Further, the "risk of credit loss should be fairly contained for the long-tenured disciplined multi-family lenders," she added. Following the news, shares of Signature Bank (SBNY) are down 3% to $117.18, Dime Community (DCOM) shares are down 12c to $18.66 and New York Community Bancorp (NYCB) is down 3% to $10.06.
03/11/19
MSCO
03/11/19
DOWNGRADE
MSCO
Underweight
New York Community downgraded to Underweight from Equal Weight at Morgan Stanley
03/11/19
MSCO
03/11/19
DOWNGRADE
Target $11.5
MSCO
Underweight
New York Community Bancorp downgraded to Underweight at Morgan Stanley
Morgan Stanley analyst Ken Zerbe downgraded New York Community to Underweight from Equal Weight after cutting his loan growth expectations citing the intensifying competition from non-bank lenders. Given competition, including from private equity debt funds, Zerbe thinks consensus expectations for the bank's loan growth are too optimistic, he tells investors. The analyst, who believes slowing and below-consensus loan growth, combined with ongoing NIM compression, are not being sufficiently discounted, has an $11.50 price target on New York Community Bancorp shares.
04/08/19
JEFF
04/08/19
INITIATION
Target $12
JEFF
Hold
New York Community Bancorp initiated with a Hold at Jefferies
Jefferies analyst Casey Haire started New York Community Bancorp with a Hold rating and $12 price target. The company's profitability is "poised to rebound" thanks to a dovish Fed policy and deregulation, but its valuation reflects this with the shares trading at a 28% premium to peers, Haire tells investors in a research note.
GBT Global Blood Therapeutics
$57.45

(0.00%)

06/14/19
CANT
06/14/19
NO CHANGE
Target $110
CANT
Overweight
Global Blood price target raised to $110 from $96 at Cantor Fitzgerald
Cantor Fitzgerald analyst Elemer Piros raised his price target for Global Blood Therapeutics to $110 from $96 saying the Hope trial indicates "disease-modifying potential" of voxelotor in sickle cell disease. The analyst reiterates an Overweight rating on the shares. Global Blood in premarket trading is down 6%, or $3.22, to $54.30.
06/14/19
WELS
06/14/19
NO CHANGE
WELS
Outperform
Global Blood Therapeutics data should support 'rapid approval,' says Wells Fargo
Wells Fargo analyst Jim Birchenough reiterates an Outperform rating on Global Blood Therapeutics following release of the final Hope Phase 3 results for hemoglobin modifier voxelotor in sickle cell disease. The analyst expects the data to support "rapid approval and commercial success" in sickle cell. He notes that no patient discontinued due to an adverse event with the exception of a single patient in the placebo group.
06/03/19
WEDB
06/03/19
NO CHANGE
Target $107
WEDB
Outperform
Global Blood Therapeutics price target raised to $107 from $95 at Wedbush
Wedbush analyst Liana Moussatos raised her price target for Global Blood Therapeutics to $107 from $95 given reduced clinical, regulatory, commercial and manufacturing risk along with sufficient cash for initial U.S. launch, strong IP and upside potential from multiple potentially material catalysts and as more investors appreciate that FDA is not solely focused on VOC as a primary endpoint for SCD. The analyst reiterates an Outperform rating on the shares.
05/29/19
GSCO
05/29/19
INITIATION
Target $75
GSCO
Neutral
Global Blood Therapeutics assumed with a Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi assumed coverage of Global Blood Therapeutics with a Neutral rating and $75 price target. Prior analyst Terence Flynn had a Neutral rating on the shares with a $59 price target. Choi believes the company's lead asset voxelotor could "shift the paradigm" in the treatment of sickle cell disease, but he believes investors should await more more visibility on the clinical and commercial outcomes.
AVGO Broadcom
$281.95

(0.00%)

06/14/19
JEFF
06/14/19
NO CHANGE
Target $324
JEFF
Buy
Broadcom price target lowered to $324 from $370 at Jefferies
Jefferies analyst Mark Lipacis lowered his price target for Broadcom to $324 from $370 after the company reduced its revenue outlook but he keeps a Buy rating on the shares. The analyst expects an inventory restock in the second half of 2019 and view Broadcom's risk/reward as attractive.
06/14/19
CHLM
06/14/19
NO CHANGE
Target $315
CHLM
Buy
Broadcom price target lowered to $315 from $325 at Craig-Hallum
Craig-Hallum analyst Anthony Stoss reiterated a Buy rating on Broadcom (AVGO) but lowered his price target to $315 after the company reported revenues below the Street and his estimate due to the impact of the Huawei ban as well as Apple (AAPL) weakness. Stoss tells investors in a research note that he still expects Broadcom to benefit from content growth at Apple this year due to the socket win back from Qorvo (QRVO) and new content associated with Wi-Fi 6 and says he continues to like Broadcom's position at Apple longer term and notes its recently signed two-year supply agreement positions the company well for 5G inclusion in iPhones likely coming next year.
06/14/19
DADA
06/14/19
NO CHANGE
Target $300
DADA
Buy
Broadcom price target lowered to $300 from $325 at DA Davidson
DA Davidson analyst Thomas Diffely lowered his price target on Broadcom to $300 after the company reported a "light" quarter and cut its outlook for the year because of a sharper than anticipated slowdown in Wireless, softness in Storage, and the loss of revenue associated with the Huawei export restrictions. The analyst says he is also adopting a "more conservative" near-term stance, taking Huawei completely out of his model and cutting his FY20 EPS estimates to $24 from $26 per shares to reflect the continued China trade war and inventory digestion by key OEM customers. Longer term however, Diffely keeps his Buy rating on Broadcom given the company's "product diversity, operational track record, cash generation, and best in class margins."
06/14/19
RHCO
06/14/19
NO CHANGE
Target $307
RHCO
Buy
Broadcom price target lowered to $307 from $339 at SunTrust
SunTrust analyst William Stein lowered his price on Broadcom to $307 after its "mixed" Q1 results and reduced FY19 guidance "poured cold water" on the expected second-half of 2019 recovery in semiconductors. The analyst cites the management's acknowledgement that trade tensions and Huawei export ban make expectations of a second-half recovery unrealistic, but keeps his Buy rating on Broadcom and contends that the 8% sell-off in the stock price during the afterhours session was "at least partly overdone". Stein cuts his FY19 and FY20 EPS estimates by 33c and $2.68 to $22.24 and $24.98, but notes that Broadcom offers "good" margin stability, traction in CA Technologies performance, and dividend growth trajectory.
DIS Disney
$141.73

(0.00%)

06/14/19
LOOP
06/14/19
NO CHANGE
Target $165
LOOP
Buy
Disney price target raised to $165 from $140 at Loop Capital
Loop Capital analyst Alan Gould raised his price target on Disney to $165 and kept his Buy rating, saying the company's 5% discount to premium valuation range relative to the S&P500 will be "revalued" if the company can transform itself into a Direct-to-Consumer service provider. The analyst expects Disney's success to be "initially" measured by Disney+ subscriptions and believes that its first year count will top the 10M consensus.
06/13/19
MSCO
06/13/19
NO CHANGE
Target $160
MSCO
Overweight
Disney price target raised to $160 at Morgan Stanley on higher DTC forecasts
Morgan Stanley analyst Benjamin Swinburne raised his subscriber growth forecast for Disney+, Disney's upcoming direct-to-consumer streaming service, stating that he expects Disney+ to be trending towards 13M subs a year from now. Combined with Hulu and ESPN+, the company will have an OTT subscriber base of over 50M by the end of FY20 and he now forecast over 130M global OTT subscribers by FY24, Swinburne tells investors. A higher expected revenue scale for its DTC offerings, combined with an expectation for DTC profitability in FY24, leads the analyst to forecast over $11 of adjusted EPS in FY24 for Disney and prompted him to raise his price target on the stock to $160 from $135. Swinburne keeps an Overweight rating on Disney shares.
05/13/19
PIPR
05/13/19
NO CHANGE
Target $440
PIPR
Overweight
Piper survey shows limited risk to Netflix from Disney streaming service
Piper Jaffray asked 1,536 U.S. Netflix (NFLX) subscribers if they would subscribe to both Disney's (DIS) new streaming service and Netflix, only Netflix or only Disney+, analyst Michael Olson tells investors in a research note. Piper indicated that the Disney+ price point is $7 per month, which it believes will prove to be only an introductory price. The results show that 73% of U.S. Netflix subscribers do not expect to subscribe to Disney+, 20% expect to subscribe to both services, and only 7% indicated that they will cancel Netflix and subscribe to Disney+, Olson tells investors in a research note. The results suggest Netflix's risk of share loss is limited to a small percentage of its base, concludes the analyst. As such, he expects Netflix to continue to "capture a significant portion of the tidal wave of traditional content dollars that are migrating to streaming." Olson maintains an Overweight rating on Netflix shares with a $440 price target. The stock closed Friday down $1.71 to $361.04.
05/15/19
MSCO
05/15/19
NO CHANGE
MSCO
Overweight
Disney will have 'high class problem' if it has to pay more for Hulu, says Morgan Stanley
After Disney (DIS) and Comcast (CMCSA) announced a new agreement regarding their Hulu joint venture, Morgan Stanley analyst Benjamin Swinburne said the new pact is indicative of the priorities of both companies. Operational control of Hulu give Disney a chance to bundle the service with Disney Plus and/or ESPN Plus, allows for international expansion and likely creates some cost synergies, said Swinburne, who added that Disney will have "a high class problem" if it turns out if Hulu is appraised at a higher value when it comes time to buy out Comcast. For Comcast, the new deal gives it downside protection and content flexibility as it builds out its own streaming plans, the analyst added. He keeps Overweight ratings on both Disney and Comcast, concluding that the deal between the media giants will accelerate the transition from legacy TV to streaming.
FB Facebook
$177.47

(0.00%)

06/11/19
MOFT
06/11/19
UPGRADE
Target $210
MOFT
Buy
Facebook upgraded to Buy from Neutral at MoffettNathanson
MoffettNathanson analyst Michael Nathanson upgraded Facebook to Buy from Neutral with a $210 price target.
06/13/19
DBAB
06/13/19
NO CHANGE
DBAB
Buy
Facebook Watch sales can top $5B in next few years, says Deutsche Bank
Deutsche Bank analyst Lloyd Walmsley says he's encouraged by stats released from Facebook yesterday showing "strong" improvements in audience and engagement at Facebook Watch. The analyst increasingly sees Watch as a scalable long-term revenue source. However, most investors view Watch as "meh" to the investment case, skeptical it can scale despite some solid numbers released in December, Walmsley tells investors in a research note. Nonetheless, the analyst believes yesterday's stats can start to bring Watch "back to the fore among investors as an emerging part of the medium-term bull case." Walmsley sees a path to Watch becoming a greater than $5B annual business for Facebook in the next few years. With that said, Watch could be a drag on overall revenue in the short term to the extent that time spent cannibalizes core Facebook newsfeed and caries 55% revenue-sharing with content creators, he adds. The analyst keeps a Buy rating on Facebook shares.
06/11/19
06/11/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Facebook (FB) upgraded to Buy from Neutral at MoffettNathanson. 2. Red Rock Resorts (RRR) upgraded to Buy from Neutral at Goldman Sachs with analyst Stephen Grambling saying he sees 35% total return potential in the stock as he believes a successful Palms ramp and free cash flow "inflection" in 2020 can drive a "sustained re-rating." 3. JetBlue (JBLU) upgraded to Buy from Neutral at Citi with analyst Kevin Crissey saying JetBlue has positive catalysts to support incremental buyers with a range of time horizons and investment styles. 4. Lyft (LYFT) upgraded to Positive from Neutral at Susquehanna. 5. Dollar Tree (DLTR) resumed with an Overweight from Neutral at JPMorgan with analyst Matthew Boss saying he expects an inflection to high-single net income growth and low-double-digit consolidated earnings growth beyond fiscal 2019 as the Dollar Tree offers stability and Family Dollar improves. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/14/19
CHLM
06/14/19
NO CHANGE
CHLM
Buy
Facebook cryptocurrency would be 'positive' for PayPal, says Craig-Hallum
Craig-Hallum analyst Brad Berning tells investors in a research note that a Facebook (FB) cryptocurrency would be a "positive" for Buy-rated PayPal (PYPL), as it could drive higher adoption of Braintree merchant acceptance and the Facebook marketplace, which according to CFO John Rainey, could dwarf eBay (EBAY).
JNUG Direxion Daily Jr Gld Mnrs Bull 3X Shrs
$8.96

(0.00%)

SBUX Starbucks
$83.36

(0.00%)

06/12/19
SBSH
06/12/19
NO CHANGE
SBSH
Citi survey shows little impact to Starbucks in China from trade war
Citi analyst Gregory Badishkanian says his survey of over 300 Chinese coffee market consumers indicated the consumers are "generally indifferent" about purchasing American goods versus 12 months ago. This suggests relatively little impact to Starbucks (SBUX) from the recent geopolitical disputes, Badishkanian tells investors in a research note. Further, the survey shows Starbucks is leading on taste while competitors are leading on price, adds the analyst.
06/11/19
EVER
06/11/19
INITIATION
Target $82
EVER
In Line
Starbucks initiated with an In Line at Evercore ISI
Evercore ISI analyst David Palmer started Starbucks with an In Line rating and $82 price target.
06/10/19
PIPR
06/10/19
NO CHANGE
Target $82
PIPR
Neutral
Starbucks price target raised to $82 from $77 at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan raised her price target for Starbucks to $82 from $77 saying her key takeaway from the company's keynote last week at her firm's conference is "improving performance momentum exists." However, the current valuation "now overshadows the current compelling aspects of the business," Regan tells investors in a research note. As such, she reiterates a Neutral rating on Starbucks shares.
06/07/19
CLVD
06/07/19
NO CHANGE
CLVD
Neutral
Starbucks' U.S. comp growth accelerated to start Q3, says Cleveland Research
Cleveland Research analyst Steven Gojak said in a note to investors earlier that his checks indicate that U.S. comparable sales have accelerated at Starbucks to start Q3, which is being offset by some moderation in Canada. The analyst, who sees Americas comps trending above consensus in the quarter-to-date, keeps a Neutral rating on Starbucks shares, which are up $1.55, or 1.9%, to $82.94 in early trading.
GOLD Barrick Gold
$13.86

(0.00%)

04/10/19
DBAB
04/10/19
DOWNGRADE
Target $10
DBAB
Hold
Ryerson downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Chris Terry downgraded Ryerson to Hold from Buy and lowered his price target for the shares to $10 from $12. The analyst increased his precious metal exposure by upgrading both Barrick Gold (GOLD) and Pan American Silver (PAAS), but he's "not outright positive" on the Metals & Mining sector. While the analyst is still cautious on the stability of conditions in China, he notes there has been an improvement in growth conditions and "some strides" towards a trade deal with the U.S.
04/10/19
DBAB
04/10/19
UPGRADE
Target $15
DBAB
Buy
Deutsche upgrades Barrick to Buy on more favorable gold view
Deutsche Bank analyst Chris Terry upgraded Barrick Gold to Buy from Hold and raised his price target for the shares to $15 from $12.75. The analyst cites valuation for the upgrade after his firm's increased its view on gold prices. Further, he believes cost-out opportunities, synergies in Nevada and potential divestment opportunities that could provide positive catalysts for Barrick shares.
05/23/19
SBSH
05/23/19
DOWNGRADE
SBSH
Neutral
Barrick Gold downgraded to Neutral from Buy at Citi
05/23/19
SBSH
05/23/19
NO CHANGE
Target $12.5
SBSH
Neutral
Citi upgrades Newmont, downgrades Barrick on resumption of coverage
Citi analyst Alexander Hacking resumed coverage of Barrick Gold and downgraded the shares to Neutral from Buy while lowering his price target to $12.50 from $14. He also resumed coverage of Newmont Mining (NEM) and upgraded the shares to Buy from Neutral while raising his price target for the shares to $40 from $36. The gold sector remains challenged, but Newmont offers better value than Barrick, Hacking tells investors in a research note. After applying Barrick's 1.2 times multiple to Newmont's holdings in the joint venture assets, the analyst sees Newmont's other assets trading at only 0.76 times net asset value. This could be re-rated higher as the market starts to incorporate the joint venture into models, says Hacking.
LULU Lululemon
$174.51

(0.00%)

06/14/19
BERN
06/14/19
NO CHANGE
BERN
Lululemon valuation can be sustained with SSS in double digits, says Bernstein
Bernstein analyst Jamie Merriman maintained 2019 EPS estimate of $4.62 following lululemon's Q1 results, and raised her 2020 EPS estimate to $5.60 due to stronger than expected direct to consumer growth in Q1 driving increased topline. In a research note to investors, Merriman says that while she believes lululemon's valuation can be sustained as long as total comp sales growth continues in the double digits, she struggles to find room for upside in the medium to long term.
06/13/19
NEED
06/13/19
NO CHANGE
NEED
Hold
Needham looking for better entry point on Lululemon
Needham analyst Rick Patel kept his Hold rating on Lululemon but said he is looking for a "better entry opportunity" on the stock after its "strong" Q1 results, saying the quarter marked a "continuation" of the company's execution across products, channels, and geographies. The analyst notes that although the magnitude of the earnings beat was relatively smaller, the results were "favorable" against the backdrop of a challenging retail environment. Patel believes that Lululemon can continue to generate strong comps, even though its gross margin expansion will slow as the company "laps significant product cost-related improvements."
06/13/19
DADA
06/13/19
NO CHANGE
Target $180
DADA
Neutral
Lululemon price target raised to $180 from $155 at DA Davidson
DA Davidson analyst John Morris raised his price target on Lululemon to $180 after its Q1 earnings beat driven by better than expected comps and gross margins that were "slightly offset" by the company's planned SG&A increases. The analyst notes that the company is setting up for "growth-driving investments" in Q2 and beyond while raising his FY19 EPS view to $4.77 from $4.63, but also points to the headwinds of tougher comps of 19%, 18%, and 17% in Q2, Q3, and Q4 of 2019. Morris keeps his Neutral rating on Lululemon and adds that as gross margins approach their historically high levels, upside for further expansion diminishes.
06/13/19
JEFF
06/13/19
NO CHANGE
Target $175
JEFF
Hold
Lululemon price target raised to $175 from $156 at Jefferies
Jefferies analyst Randal Konik raised his price target for Lululemon Athletica to $175 from $156 following the company's Q1 results. Lululemon posted strong traffic, strong new and existing customer growth as well as pricing power, Konik tells investors in a research note. He admits he downgraded the shares "way too early" and keeps a Hold rating on the name despite raising his numbers.
SLV iShares Silver Trust
$13.95

(0.00%)

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

, GRUB

GrubHub

$70.15

-2.76 (-3.79%)

13:28
06/15/19
06/15
13:28
06/15/19
13:28
Periodicals
Amazon exit gives GrubHub stock boost, Barron's says »

Amazon (AMZN) is…

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

, CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

13:20
06/15/19
06/15
13:20
06/15/19
13:20
Periodicals
McKesson, Cardinal Health looking like bargains, Barron's says »

Investors have halved the…

ABC

AmerisourceBergen

$85.01

-1.46 (-1.69%)

CAH

Cardinal Health

$44.16

-1.13 (-2.50%)

MCK

McKesson

$133.19

-1.7 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

RTN

Raytheon

$177.38

0.195 (0.11%)

, UTX

United Technologies

$125.30

0.45 (0.36%)

13:09
06/15/19
06/15
13:09
06/15/19
13:09
Periodicals
United Technologies, Raytheon stocks looking cheap, Barron's says »

Shares of United…

RTN

Raytheon

$177.38

0.195 (0.11%)

UTX

United Technologies

$125.30

0.45 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

, AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

13:04
06/15/19
06/15
13:04
06/15/19
13:04
Periodicals
Food fight extending well beyond restaurant delivery, Barron's says »

Amazon (AMZN) is quitting…

GRUB

GrubHub

$70.15

-2.76 (-3.79%)

AMZN

Amazon.com

$1,870.07

-0.23 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

  • 27

    Jun

  • 10

    Jul

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

, GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

12:59
06/15/19
06/15
12:59
06/15/19
12:59
Periodicals
Facebook, JPMorgan chiefs among Best CEOs of 2019, Barron's says »

Separated into three…

GOOGL

Alphabet Class A

$1,086.36

-4.65 (-0.43%)

GOOG

Alphabet

$1,085.56

-3.52 (-0.32%)

FB

Facebook

$181.35

3.88 (2.19%)

MCD

McDonald's

$205.33

0.85 (0.42%)

JPM

JPMorgan

$109.84

0.26 (0.24%)

BAC

Bank of America

$28.03

0.09 (0.32%)

BLK

BlackRock

$446.96

-1.29 (-0.29%)

BX

Blackstone

$44.13

0.17 (0.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 19

    Jun

  • 09

    Jul

  • 10

    Jul

  • 16

    Jul

  • 17

    Jul

  • 06

    Aug

  • 27

    Oct

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

, AAPL

Apple

$192.84

-1.93 (-0.99%)

07:17
06/15/19
06/15
07:17
06/15/19
07:17
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AVGO

Broadcom

$265.99

-15.96 (-5.66%)

AAPL

Apple

$192.84

-1.93 (-0.99%)

HNHPF

Hon Hai Precision

$0.00

(0.00%)

UTX

United Technologies

$125.30

0.45 (0.36%)

RTN

Raytheon

$177.38

0.195 (0.11%)

CGC

Canopy Growth

$41.15

-0.64 (-1.53%)

TLRY

Tilray

$38.96

-1.78 (-4.37%)

APHA

Aphria

$6.80

-0.15 (-2.16%)

ACB

Aurora Cannabis

$7.56

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

CNTTF

CannTrust Holdings

$0.00

(0.00%)

CRON

Cronos Group

$15.43

-0.92 (-5.63%)

CANN

General Cannabis

$0.00

(0.00%)

IGC

India Globalization Capital

$1.28

0.4201 (48.85%)

MLCPF

MediPharm Labs

$0.00

(0.00%)

ZYNE

Zynerba

$13.03

-0.54 (-3.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 17

    Jun

  • 18

    Jun

  • 19

    Jun

  • 21

    Jun

  • 25

    Jun

  • 09

    Jul

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, ABMD

Abiomed

$250.96

-4.58 (-1.79%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
International League of Dermatological Societies to hold a conference »

24th World Congress of…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

ABMD

Abiomed

$250.96

-4.58 (-1.79%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

JNJ

Johnson & Johnson

$140.08

-0.63 (-0.45%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PG

Procter & Gamble

$111.20

0.28 (0.25%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

UL

Unilever; also tag UN

$62.61

-0.07 (-0.11%)

UN

Unilever; also tag UL

$61.30

-0.13 (-0.21%)

INCY

Incyte

$77.76

1.385 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 17

    Jun

  • 26

    Jun

  • 27

    Jun

  • 16

    Jul

  • 25

    Jul

  • 30

    Jul

  • 28

    Aug

  • 03

    Sep

  • 16

    Sep

  • 13

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

, GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Congress of Rheumatology to hold a conference »

EULAR 2019 will be held…

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

PFE

Pfizer

$42.75

0.24 (0.56%)

LLY

Eli Lilly

$111.74

-0.06 (-0.05%)

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

RHHBY

Roche

$0.00

(0.00%)

BIIB

Biogen

$227.67

-3.57 (-1.54%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

REGN

Regeneron

$305.19

-2.235 (-0.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 25

    Jul

  • 30

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

ABT

Abbott

$82.25

-0.03 (-0.04%)

, AMGN

Amgen

$176.09

-0.74 (-0.42%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
Society for Vascular Surgery to hold annual meeting »

SVS Annual Meeting 2019…

ABT

Abbott

$82.25

-0.03 (-0.04%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

BSX

Boston Scientific

$40.41

-0.26 (-0.64%)

PFE

Pfizer

$42.75

0.24 (0.56%)

CRY

CryoLife

$29.13

-0.13 (-0.44%)

EW

Edwards Lifesciences

$184.00

-0.63 (-0.34%)

ELGX

Endologix

$7.61

0.2 (2.70%)

IAC

IAC

$228.41

-2.63 (-1.14%)

HCA

HCA Healthcare

$126.64

-0.76 (-0.60%)

LMAT

LeMaitre

$26.04

-0.44 (-1.66%)

ORGO

Organogenesis

$7.39

0.02 (0.27%)

OSIR

Osiris

$0.00

(0.00%)

PEN

Penumbra

$166.75

2.93 (1.79%)

SWAV

ShockWave Medical

$58.27

-0.99 (-1.67%)

WTKWY

Wolters Kluwer

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jun

  • 26

    Jun

  • 09

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 16

    Sep

  • 25

    Sep

  • 13

    Nov

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

, INCY

Incyte

$77.76

1.385 (1.81%)

04:55
06/15/19
06/15
04:55
06/15/19
04:55
Conference/Events
European Hematology Association to hold a conference »

24th EHA Congress 2019…

ABBV

AbbVie

$78.69

-0.27 (-0.34%)

INCY

Incyte

$77.76

1.385 (1.81%)

ARQL

ArQule

$8.17

1.88 (29.89%)

AMGN

Amgen

$176.09

-0.74 (-0.42%)

ALXN

Alexion

$117.94

0.65 (0.55%)

AGIO

Agios Pharmaceuticals

$47.97

-1.78 (-3.58%)

AZN

AstraZeneca

$39.68

-0.23 (-0.58%)

BLUE

Bluebird Bio

$117.57

-6.33 (-5.11%)

BMY

Bristol-Myers

$47.57

0.25 (0.53%)

CELG

Celgene

$96.49

0.07 (0.07%)

NVS

Novartis

$89.52

-0.07 (-0.08%)

NSTG

NanoString

$25.96

0.45 (1.76%)

KPTI

Karyopharm

$5.71

-0.04 (-0.70%)

JAZZ

Jazz Pharmaceuticals

$130.43

0.28 (0.22%)

GSK

GlaxoSmithKline

$40.12

0.015 (0.04%)

GILD

Gilead

$66.38

-0.62 (-0.93%)

DSNKY

Daiichi Sankyo

$0.00

(0.00%)

PFE

Pfizer

$42.75

0.24 (0.56%)

PTLA

Portola Pharmaceuticals

$25.78

-0.31 (-1.19%)

QGEN

Qiagen

$39.52

-0.07 (-0.18%)

RHHBY

Roche

$0.00

(0.00%)

RIGL

Rigel Pharmaceuticals

$2.06

-0.06 (-2.83%)

SNY

Sanofi

$42.46

-0.225 (-0.53%)

SGEN

Seattle Genetics

$68.67

-0.33 (-0.48%)

STML

Stemline

$14.20

0.12 (0.85%)

VSTM

Verastem

$1.39

0.125 (9.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jun

  • 17

    Jun

  • 18

    Jun

  • 20

    Jun

  • 20

    Jun

  • 20

    Jun

  • 21

    Jun

  • 23

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 26

    Jun

  • 27

    Jun

  • 27

    Jun

  • 27

    Jun

  • 28

    Jun

  • 28

    Jun

  • 06

    Jul

  • 25

    Jul

  • 06

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 26

    Aug

  • 28

    Aug

  • 29

    Aug

  • 02

    Sep

  • 03

    Sep

  • 16

    Sep

  • 04

    Nov

  • 04

    Dec

  • 25

    Mar

  • 04

    Apr

CNC

Centene

$53.52

-0.26 (-0.48%)

, WCG

WellCare

$287.16

0.145 (0.05%)

18:45
06/14/19
06/14
18:45
06/14/19
18:45
Hot Stocks
Centene CEO: Medicare for all will not work »

In an interview on…

CNC

Centene

$53.52

-0.26 (-0.48%)

WCG

WellCare

$287.16

0.145 (0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jun

  • 24

    Jun

  • 24

    Jun

  • 23

    Jul

HMC

Honda

$25.34

-0.405 (-1.57%)

18:24
06/14/19
06/14
18:24
06/14/19
18:24
Hot Stocks
Honda recalls all 2016-2019 model year Pioneer vehicles »

Honda is conducting a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$111.28

1.42 (1.29%)

18:22
06/14/19
06/14
18:22
06/14/19
18:22
Hot Stocks
RH CEO: We think our stock is massively undervalued »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISH

Dish

$37.54

-0.35 (-0.92%)

, S

Sprint

$7.01

0.2 (2.94%)

18:08
06/14/19
06/14
18:08
06/14/19
18:08
Periodicals
Dish leads bidding for Sprint, T-Mobile assets, WSJ reports »

Dish Network (DISH) is…

DISH

Dish

$37.54

-0.35 (-0.92%)

S

Sprint

$7.01

0.2 (2.94%)

TMUS

T-Mobile

$74.90

0.44 (0.59%)

CHTR

Charter

$392.20

2.76 (0.71%)

ATUS

Altice USA

$23.82

0.15 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$32.69

-0.39 (-1.18%)

17:31
06/14/19
06/14
17:31
06/14/19
17:31
Periodicals
American Air asks court to end 'devastating' work slowdown, Bloomberg says »

American Airlines urged a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ROLL

RBC Bearings

$150.43

-3.38 (-2.20%)

17:16
06/14/19
06/14
17:16
06/14/19
17:16
Hot Stocks
RBC Bearings CEO sells over 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$1.25

(0.00%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
FTE Networks granted financial viability exception by NYSE regulation »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$347.19

-1.54 (-0.44%)

17:14
06/14/19
06/14
17:14
06/14/19
17:14
Hot Stocks
Boeing awarded Air Force contract modification, increases ceiling by $6.53B »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 09

    Jul

MDR

McDermott

$7.60

-0.12 (-1.55%)

17:11
06/14/19
06/14
17:11
06/14/19
17:11
Hot Stocks
Chatterjee Fund Management reports 5.6% passive stake in McDermott »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZZA

Papa John's

$50.74

0.28 (0.55%)

17:09
06/14/19
06/14
17:09
06/14/19
17:09
Hot Stocks
Papa John's dismisses KPMG as auditors, hires Ernst & Young »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jun

  • 20

    Jun

  • 20

    Jun

  • 13

    Nov

EPZM

Epizyme

$11.62

-0.36 (-3.01%)

16:55
06/14/19
06/14
16:55
06/14/19
16:55
Conference/Events
Epizyme to hold a conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jun

CACI

CACI

$202.80

-1.205 (-0.59%)

16:54
06/14/19
06/14
16:54
06/14/19
16:54
Conference/Events
CACI to hold a conference call »

Management holds a fiscal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jun

HCR

Hi-Crush Inc.

$2.84

0.115 (4.22%)

16:53
06/14/19
06/14
16:53
06/14/19
16:53
Syndicate
Hi-Crush Inc files $1B mixed securities shelf »

The company also files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHIP

Seanergy Marine

$0.63

-0.0381 (-5.70%)

16:51
06/14/19
06/14
16:51
06/14/19
16:51
Earnings
Seanergy Marine reports Q1 EPS ($3.23), two estimates ($2.85) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FELP

Foresight Energy

$0.79

-0.04 (-4.82%)

16:46
06/14/19
06/14
16:46
06/14/19
16:46
Hot Stocks
Foresight Energy discloses NYSE listing standard notice »

Foresight Energy is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.